BofA lowered the firm’s price target on Vertex (VERX) to $24 from $34 and keeps a Neutral rating on the shares following a “disappointing” Q4 outlook. With the implied growth rate in Q4 of 9% toward ...
Vertex Pharmaceuticals Inc. reported third-quarter sales that beat analysts’ expectations as the biotech company’s mainstay ...
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 11% ...
Vertex (NASDAQ: VERX) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table below ...
Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.58 per share, up from $4.38 per share in the year-ago period. The consensus estimate for Vertex ...
Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. Learn more about VERX stock here.
Vertex Pharmaceuticals (NASDAQ: VRTX) has been one of the fastest-growing healthcare companies in recent years. Its products have made it a leader in cystic fibrosis (CF) treatment and it has been ...
Boston-based Vertex reported revenue of $3.08 billion, an 11 percent gain from one year ago. That was ahead of analysts’ ...
If You Invested $10,000 in Vertex Pharmaceuticals 5 Years Ago, This Is How Much You Would Have Today
Vertex has proved itself as a solid long-term investment. The company has reached an important turning point -- that could mean more blockbuster revenue down the road. The past few years have brought ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback